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ABSTRACT. This study presents a complete structural and biological 
characterization of Doxorubicin/CaCO3 single crystals as a pH responsive drug 
carrier. Using a biomimetic approach, it was demonstrated that calcite single crystals 
are able, during their growth in presence of doxorubicin, to entrap drug molecules 
inside their lattice, along specific crystallographic directions. High-resolution 
synchrotron powder diffraction measurements allowed the determination of the lattice 
distortion and microstructural parameters. Confocal microscopy confirmed that 
doxorubicin is uniformly embedded in the crystal and that the drug is not only 
adsorbed on the crystal surface. A slow release of DOX is obtained that occurs 
preferentially in proximity of the crystals, targeting cancer cells. 
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Nano- and micro-particles hold great promise for controlled and targeted drug release 
and delivery.1-3 An ideal drug carrier should not exert harmful effects on normal cells. 
It should also satisfy requirements of stability, in vivo biocompatibility, and ability of 
targeted on-demand release.1-3 Inorganic nanomaterials may fulfill most of these 
requirements. Due to the simplicity of synthesis and modification, it is possible to 
control the particle size, shape and surface functionalization.3  They are usually made 
of durable and robust materials, which allow encapsulation and protection of 
sufficient amounts of cargos, preventing pre-leakage and damage to normal cells.4 
Among inorganic carriers, calcium carbonate crystals represent an ideal platform as 
smart carriers for drugs due to their capability to adsorb,5-16 and more importantly to 
entrap, drugs.17 Organic molecules are commonly found incorporated inside biogenic 
calcium carbonate (CaCO3) crystals.18,19 Nature in several organisms uses minerals to 
store vital ions and structural and functional molecules and macromolecules.20,21 In 
this view the use of CaCO3 as cargo-carrier represents an application of bio-
mineralization inspired principles.22-24 
CaCO3 forms common biominerals that are intimately associated to biological fluids, 
which, in turn, makes them highly biocompatible. In the body, it degrades to Ca2+ and 
CO32-, which are products that do not pose problems of toxicity.25, 26 
The preparation of CaCO3 crystals is a simple, low cost and organic solvent-free 
process (low-level exposure to residual toxic organic solvents may lead to lasting 
toxic effects). Under highly optimized conditions, crystal formation can control the 
size of CaCO3 particles from the micro- to the nano-meter range, with relatively 
narrow size distributions.27 The pH sensitive CaCO3 solubility can release entrapped 
molecules only when the dissolution of the crystals occurs.28 Drug/CaCO3 hybrid 
crystals allows zero-leakage of drugs at the physiological pH of 7.4, and release drugs 
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in acidic conditions. CaCO3 carriers are particularly suitable for selective release of 
drugs in tissues that are more acidic than normal physiological pH (tumors, inflamed 
tissues).29,30  
In general, development of an effective drug delivery system requires understanding 
of the chemical and physical properties that affect i) the interaction of the drug with 
the micro- nano- particles, and ii) the interaction of the micro- nano- carries with the 
biological environment. Often, the structural characterization of the interaction 
between drug and carrier is missing. Dopant molecules can be either located between 
individual crystallites of polycrystalline materials or entrapped inside single crystals 
where they can interact with specific crystallographic patterns. 
In the present work, doxorubicin (DOX), an anthracycline drug widely used in 
chemotherapy,31 is used as model molecule to study the entrapment in calcite crystals 
and its release. The aim is to determine at what concentrations DOX is incorporated 
inside CaCO3 single crystals, examine the effects of such incorporation on the hosting 
crystalline lattice and understand the mechanism of incorporation. The biological 
activity of CaCO3/DOX systems is also assayed. 
 
RESULTS AND DISCUSSIONS 
Calcium carbonate/DOX hybrid crystal precipitation was conducted at room 
temperature by controlled diffusion of CO2 and NH3 vapors into 10 mM calcium 
chloride solutions containing different concentrations of DOX. The precipitation 
process was stopped after 4 days (see Methods for details). 
Effect of DOX doping on the morphology of calcite crystals. In the absence of 
DOX, only rhombohedral single crystals of calcite are precipitated. In these crystals, 
characterized by an average size of 50 µm, only the typical {10.4} faces are 
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observable. The presence of DOX influenced the crystallization process as a function 
of its initial concentration in solution. At low concentrations, 5⋅10-4 mM and 5⋅10-3 
mM, DOX did not affect the precipitation of calcite. At a concentration of 5⋅10-2 mM 
the crystals became hoppered, showing holes on the {10.4}rhombohedral faces. 
Increasing the concentration of DOX to 5⋅10-1 mM and 5 mM results in the 
observation of the co-presence of spherulites with aggregated rhombohedral crystals 
and in the strong inhibition of the precipitation that is usually associated with the 
deposition of few aggregates and submicron sized particles.  Calcite was the only 
crystalline phase detected by X-ray powder diffraction in the control experiment and 
in the experiments in which 5⋅10-4 mM, 5⋅10-3 mM or 5⋅10-2 mM DOX was used. 
When a higher concentration of DOX was used (5⋅10-1 mM and 5 mM), small 
amounts of vaterite co-precipitated with calcite (Fig. 1). This preliminary 
investigation indicated that 5⋅10-2 mM DOX was the optimal initial concentration for 
the aims of this research. 
 
Figure 1 Optical microscope pictures of DOX/calcite hybrid crystals precipitated in 
the presence of different initial concentrations of DOX. (A) no DOX, (B) 5⋅10-4 mM, 
(C) 5⋅10-3 mM, (D) 5⋅10-2 mM, (E) 5⋅10-1 mM and (F) 5 mM. Scale bar 100 µm. 
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The textural features of the DOX/calcite hybrid crystals were further investigated by 
scanning electron microscopy, as illustrated in Figure 2. 
 
Figure 2 Scanning electron microscope pictures of DOX/calcite hybrid crystals 
precipitated in the presence of 5⋅10-2 mM DOX. Textural details of different region of 
the crystal in (A) are illustrated. The rectangle indicates the region of magnification 
and the subscript the corresponding picture. 
 
Each crystal was characterized by the presence of a rounded cavity in the center of 
one of the {10.4} face. The diameter of this cavity increased from inside to outside 
and changed among crystals. The wall of the hole was stepped, with each step formed 
by a flat (10.4) face and a rough (hk.l) face. The thickness of the steps decreased from 
about 500 nm to less than 200 nm moving toward the core of the crystal. The surface 
of the (hk.l) face showed the presence of packed spheroid nanoparticles, of about 100 
nm, on which particles of few nanometers were observed. The formation of hoppers 
was explained by growth spiraling outwards from a screw dislocation32 
(thermodynamic control) and by limited diffusion of constituent ions to the growing 
crystal face33 (kinetic control). In this case, formation of additional crystalline faces 
on the hole walls supports a mechanism of thermodynamic control of growth spiraling 
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due to the screw dislocations induced by the DOX – calcite interaction. This aspect 
was further investigated by X-ray diffraction analysis.     
 
Effect of DOX doping on the lattice structure of calcite crystals. To examine the 
influence of DOX on the crystal structure of calcite hybrid crystals in the presence of 
the optimal concentration 5⋅10-2 mM of DOX, high-resolution synchrotron powder 
diffraction (HRXRD) measurements were carried out on the 11-BM beamline 
(Argonne National Laboratory, Argonne, USA).  These measurements allowed us, by 
determination of lattice distortions, to ascertain whether DOX indeed is incorporated 
into the calcite lattice. We have already demonstrated that when organic molecules 
are incorporated into an inorganic crystalline host they induce lattice distortions34-37, 
and lead to unique microstructures.38,39 This has been shown both in biogenic crystals 
as well as in bio-inspired calcite40 and ZnO.41,42 The procedure of measurement has 
been described extensively elsewhere. In short, we applied Rietveld analysis and line 
profile analysis on the full diffraction patterns. 
The measurements were performed on the control calcite sample, DOX/calcite 
hybrid sample and on the DOX/calcite hybrid sample after a mild thermal annealing 
at 250° C for 2h. Analysis of the diffraction patterns indicates a single calcite phase in 
all measured samples (see Figure 3 as an example). 
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Figure 3. HRXRD diffraction profile of the DOX/calcite hybrid crystals 
precipitated in the presence of 5⋅10-2 mM DOX.  
 
Observing the (104) diffraction peak of DOX/calcite hybrid crystals as 
compared to the control sample demonstrates a clear peak shift towards a smaller 
Bragg angle, which indicates lattice expansion (see Figure 4). This lattice distortion is 
due to the incorporation of DOX inside the calcite crystal. In Figure 4 the (104) 
diffraction peak of the hybrid crystal is split. The splitting is due to the fact that the 
majority of the crystals well incorporate DOX, while the minority of the crystals do 
not. After the mild annealing treatment the diffraction peak shifts back to that of the 
control position due to lattice distortion relaxation as the organics are burnt out. It can 
also be seen that the post-annealing peak becomes considerably wider, the FWHM 
doubles (from 0.006° to 0.0126°) and is symmetrical. This latter phenomenon was 
also observed in previous cases such as for biogenic crystals38 and for crystals that 
contained amino acids incorporation.40,42 The cause of the broadening after annealing 
has been discussed previously, but in short, stems from the formation of new 
interfaces as the organics are burnt out. 
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Figure 4. The (104) calcite diffraction peak for control calcite (blue), DOX/calcite 
hybrid crystals (green) and after thermal annealing (red).  
 
Rietveld structure refinement analysis was applied to all diffraction spectra 
utilizing the GSAS software43 and the EXPGUI interface.44 This analysis provided 
lattice distortion determination by comparing the lattice parameters to that of the 
control sample. The summary of the lattice distortions and unit cell volumes are listed 
in Table 1. The strain along the a and c axes are almost equivalent (~8⋅10-4) and of 
positive sign (i.e., expansion) (see Figure 5). The magnitude of the distortions is 
similar to what we find both in biogenic crystals and in other biomimetic crystals. 
After the annealing process, the lattice distortions drop practically to zero within our 
statistical error. This is due to the complete destruction of the organic molecules 
within the crystalline lattice. The volume change due to the incorporation is 0.24 %, 
which might imply that the level of DOX incorporation is about 0.24% in volume.  
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Table 1. Quantitative data of lattice parameters, lattice distortions, unit cell volume 
and goodness of fit parameters for the Rietveld refinement fit (χ2). 
DOX 
concentration in 
solution (mM)  
a, b 
parameters (Å) 
strain 
a-axis 
c 
parameter (Å) 
strain 
c-axis 
unit cell 
volume (Å3) 
χ² 
- 4.990380 - 17.063950 - 368.03 4.334 
5·10-2 4.994405 8.066E-04 17.077791 8.111E-04 368.92 2.303 
5·10-2 Annealed 4.990319 -1.222E-05 17.064249 1.752E-05 368.02 3.754 
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Figure 5. Lattice distortions before and after thermal annealing for DOX/calcite 
hybrids as compared to calcite control. 
 
We further performed line profile analysis on the diffraction spectra. This 
allowed extraction of microstructural parameters (coherence length and micro-strain 
fluctuations). Single diffraction peaks were fitted to a Voigt function, which enabled 
independent evaluation of the contributions of the Lorentzian and Gaussian types, 
which correlate to the coherence length (crystalline size) and micro-strain fluctuations 
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respectively. The profile fitting was performed using the Gnuplot 4.7 interface45 over 
the most intense calcite (104) peak (Figure 6). The results revealed noticeable 
reduction in crystallite size (threefold) upon annealing accompanied by an increase in 
the averaged micro-strain fluctuations. This latter finding coincides with that observed 
for biogenic and other biomimetic crystals in which intra-crystalline organic 
molecules exist. 
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Figure 6. Crystallite size (nm) (a) and micro-strain fluctuations (b) before 
(blue square) and after (red circle) thermal annealing at 250 °C for 120 min for the 
DOX/calcite hybrid crystals along the (104) crystallographic plane. 
 
Quantification and distribution of DOX in the DOX/calcite hybrid crystals.  
An  evaluation of the total amount of DOX adsorbed in the calcite crystal was carried 
out by combining UV-vis spectroscopy, for the determination of DOX, and flame 
atomic absorption spectroscopy, for the determination of Ca2+.  A loading of 0.3 ± 0.1 
% (w/w) was calculated for the DOX/calcite hybrid crystals. 
The spatial distribution of DOX in calcite crystals was also evaluated by assessing the 
DOX fluorescence by confocal laser scanning microscopy. Figure 7 shows the 
fluorescence images obtained by a z-stacking of DOX containing crystals. All 
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longitudinal sections of the crystal display a homogeneous fluorescence intensity 
indicating that DOX was uniformly embedded in the crystal and that the drug is not 
only adsorbed on the crystal surface. No luminescence could be detected from the 
reference crystal grown in the absence of DOX  
 
 
 
Figure 7. Single xy plane (a,b) and 3D reconstruction (c,d) of a z-stacking of a 
DOX/calcite crystal in fluorescence (a, c) and reflection mode (b, d). The photo-
detector was set up in the wavelength range of the DOX emission and of the DOX 
excitation.  
 
Targeted DOX release. As expected, the drug carrier was pH-sensitive (Fig. 8). The 
DOX release kinetics from DOX/calcite crystals was measured by UV-Vis 
spectrophotometry in citrate buffer at pH 5.6. The release of DOX was still active 
after 72 hrs. The same measurements performed at pH 7.4 in PBS did not show any 
detectable release of DOX. 
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Figure 8. Kinetics of DOX release from DOX/calcite hybrid crystals in citrate buffer 
at pH 5.6.  
 
The drug release from the hybrid crystals is controlled by the dissolution rate of the 
CaCO3 host crystals.28 
In vitro test of the DOX/calcite hybrid crystals. The pharmacological activity of 
DOX/calcite hybrid crystals was tested in vitro on cell cultures. The in vitro cancer 
model used is based on the activation of the Ras oncogenic pathway. Ras oncogene is 
frequently mutated in human cancers and the activation of the Ras signaling pathway 
provides a good experimental model to study the molecular mechanisms of cancer 
transformation. Human non-tumorigenic breast epithelial cells (MCF10A) were 
subjected to retroviral (pBabe vector) infection to express the oncogenic form of Ras, 
Ha-RasVal12 (RasV12), and the infected/RasV12 expressing cells were selected by 
puromycin. RasV12 was efficiently expressed in infected cells, leading to the 
activation of Ras signaling pathway including the downstream effector Erk kinase. 
Phenotypically, RasV12 expression resulted in altered cell morphology, filopodia-like 
structure and loss of contact inhibition, soft agar colony formation as well as in vivo 
tumorigenicity.46  
To tested the toxic effect of DOX/calcite hybrid crystals on transformed MCF10A 
cells, we cultured the cells in the medium in the presence of DOX/calcite hybrid 
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crystals or calcite crystals as control. Cell growing was followed by cell counting. The 
contrast phase optical microscopy images at 24h and 72h from plating are presented 
in Figure 9. 
Pure calcite crystals revealed no toxic effect on MCF10A transformed cells. MCF10A 
cells in the presence of these crystals followed the same cell growth curve of the 
control cells. In contrast the DOX/calcite hybrid crystals demonstrated heavy toxic 
effects for the cells (Fig. 9) and after 72 hours the mortality reached 100%. This result 
suggests that the activity of DOX is retained in the crystal and that the DOX/calcite 
hybrid crystals are able to release the drug in proper concentrations.  
 
 
Figure 9. MCF10A RasV12 cells cultured with calcite crystals (left) and DOX/calcite 
hybrid crystals (right). Acquisitions were carried out at 24 and 72 hours. 
 
The DOX uptake by MCF10A RasV12 cells from the DOX/calcite hybrid crystals 
was assessed by following DOX fluorescence signal, using confocal laser 
fluorescence microscopy (Figure 10).  After 6 hrs of cell culturing in the presence of 
the crystals, the RasV12 MCF10A cell fluorescence images clearly indicated that the 
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DOX molecules were inside the cells. The DOX signal was clear on the dissolving 
surfaces of the DOX/calcite crystals (see arrows in Fig. 10). The molecular 
distribution in the cells is in accord with previous results for the same treatment 
time.47  
 
	    
Figure 10. Uptake of DOX by cancer cells. The light blue arrows highlight the DOX 
release by the DOX/Calcite crystal. The arrows indicate the periphery of the calcite 
crystals.  
 
CONCLUSION 
In conclusion, this study presents a complete structural and biological characterization 
of DOX/CaCO3 crystals as a system to specifically target drugs to particular cells or 
tissues. The pH sensitive CaCO3 solubility can release entrapped molecules only 
when the dissolution of the crystals occurs and allows zero-leakage of drugs at the 
physiological pH. The main results can be summarized in the following points: i) 
calcite is able to host DOX molecules efficiently; ii) the entrapment occurs along 
specific crystallographic directions; iii) the release of DOX is controlled by pH and 
occurs preferentially in proximity of the surface of cancer cells; iv) the released drug 
molecules are uptake by the cancer cells, killing them. 
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METHODS 
CaCO3 crystallization experiments. A 30x30x50 cm3 crystallization chamber was 
used. Two 25 mL beakers half-full of (NH4)2CO3 (Carlo Erba) and two Petri dishes (d 
= 8 cm) full of anhydrous CaCl2 (Fluka) were placed inside the chamber. Microplates 
for cellular culture (Microplate 24 well with Lid, IWAKI) containing a round glass 
cover slip in each well were used. Into each well, 750 µL of 10 mM CaCl2 solutions 
were poured. In the experiment with DEOX the required amont of DEOX was 
dissolved in the 10 mM CaCl2 solution. The micro-plate was covered with aluminum 
foil and a hole was made over every well. After 4 days the crystals were washed three 
times with milli-Q water (resistivity 18.2 MΩ cm at 25 °C; filtered through a 0.22 µm 
membrane) and then analyzed. All the experiments were conducted at room 
temperature. The crystallization trials of CaCO3 in the different conditions were 
replicated three times. 
Microscopic observations. The optical microscope observations of CaCO3 
precipitates were made with a Leica microscope equipped with a digital camera. The 
SEM observations were conducted in a scansion electronic microscope using a 
PhenomTM microscope (FEI) for uncoated samples and a Hitachi FEG 6400 
microscope for samples after coating with gold. 
Atomic absorption spectroscopy. Atomic absorption measurements of calcium and 
magnesium were carried out with Perkin Elmer AAnalyst 100 flame and graphite 
furnace (HGA 800) spectrometer equipped with a Zeeman effect background 
corrector, and an automatic data processor. A 20-µl volume sample solution obtained 
by precipitated dissolution in 0.1 M HNO3, was injected by an auto sampler. A multi 
element hollow cathode lamp of analytes was used as radiation source. Three 
measurements were carried out for each sample. 
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X-ray diffraction analysis. X-ray diffraction analysis was performed utilizing high 
resolution synchrotron powder diffraction instrument: 11-BM beamline at Argonne’s 
Advanced Photon Source (Argonne National Laboratory, Argonne, USA). Collection 
temperature  295.0 K, calibrated wavelength 0.413842 Å. Powders were packed and 
sealed into polyimide tubes and placed in the beam. Data collected from 12 crystal 
two-axis analyzer detector.  
Confocal laser scanning microscopy. Confocal laser scanning microscopy analysis 
was carried out on cells cultured onto glass coverslips, fixed with 3% 
paraformaldehyde (Sigma) in PBS and mounted with an antifade glycerol-based 
medium. Samples were observed with a LEICA TCS SP2 confocal laser scanning 
microscope (Leica Instruments) without any further modification, the fluorescence of 
DOX molecule was used to obtain the fluorescence images. 
Measurements of the kinetics of drug release.  The kinetic of DOX release was 
studied by UV-Vis spectroscopy (Perkin-Elmer Lambda 45). The crystals dissolution 
was conducted in a 0.5 M citrate buffer solution at pH 5.6 following the absorption 
intensity of DOX molecules at 499 nm. 
Cell culture. MCF10A cells (ATCC: crl-10317) were cultured in (1:1) Dulbecco's 
Modified Eagle's Medium (DMEM) / Nutrient Mixture F-12 Ham  (Gibco-Life 
Technologies Corporation) supplemented with 5% horse serum, 20 ng/ml epidermal 
growth factor (EGF), 50 ng/ml cholera toxin, 500 ng/ml hydrocortisone and 0.01 
mg/ml insulin (Gibco-Life Technologies Corporation)2. Cells were infected using a 
puromycin-resistant retroviral construct containing an oncogenic form of Ras (pBabe-
RasV12) or using the empty vector (pBabe) as described in (REF). Forty-eight hours 
post infection cells were selected using 2 µM puromycin for 4 days.  
	   17	  
Acknowledgment. B.P. acknowledges funding from the European Research Council 
under the European Union's Seventh Framework Program (FP/2007–2013)/ERC 
Grant Agreement n° [336077]. Use of the Advanced Photon Source at Argonne 
National Laboratory (11-BM beamline) was supported by the U. S. Department of 
Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-
AC02-06CH11357. 
We thank Anastasia Brif for her contribution in a part of the data analysis.  
 
 
 
REFERENCES 1)	  Farokhzad, O. C.; Langer, R. Impact of Nanotechnology on Drug Delivery. ACS 
Nano 2009, 3, 16-20. 
2) Sun, T.; Zhang, Y. S.; Pang, B.; Hyun, D. C.; Yang, M.; Xia, Y. Engineered 
Nanoparticles for Drug Delivery in Cancer Therapy. DOI: 10.1002/anie.201403036 
3) Langer, R. Drug delivery and targeting. Nature 1998, 392 (Suppl.), 5-10.  
4) Liang, R.; Wei, M.; Evans, D. G.; Duan, X.  Inorganic Nanomaterials for 
Bioimaging, Targeted Drug Delivery and Therapeutics. Chem. Commun. 2014, 50, 
14071-14081. 
5)	  Qiu, N.; Yin, H.; Ji, B.; Klauke, N.; Glidle, A.; Zhang, Y.; Song, H.; Cai, L.; Ma, 
L.; Wang, G.; Chen, L.; Wang, W. Calcium Carbonate Microspheres as Carriers for 
the Anticancer Drug Camptothecin. Mater. Sci. Eng. C 2012, 32, 2634–2640 
6) Wang, J.; Chen, J.; Zong, J.; Zhao, D.; Li, F.; Zhuo, R.; Cheng, S. Calcium 
Carbonate/Carboxymethyl Chitosan Hybrid Microspheres and Nanospheres for 
Drug Delivery. J. Phys. Chem. C 2010, 114, 18940-18945 
	   18	  
7)	  Chen, S.; Zhao, D.; Li, F.; Zhuo, R.; Cheng, S. Co-delivery of Genes and Drugs 
with Nanostructured Calcium Carbonate for Cancer Therapy. RSC Advances, 2012, 2, 
1820-1826. 
8) Wang, C.; He, C.; Tong, Z.; Liu, X.; Ren, B.; Zeng, F. Combination of Adsorption 
by Porous CaCO3 Microparticles and Encapsulation by Polyelectrolyte Multilayer 
Films for Sustained Drug Delivery. Int. J. Pharm. 2006, 308, 160-167. 
9) Ueno, Y.; Futagawa, H.; Takagi, Y.; Ueno, A.; Mizushima, Y. Drug-Incorporating 
Calcium Carbonate Nanoparticles for a New Delivery System. J. Contr. Rel. 2005, 
103 93-98. 
10) Cui, W.; Cui, Y.; Zhaoa, J.; Li, J. Fabrication of Tumor Necrosis Factor-Related 
Apoptosis Inducing Ligand (TRAIL)/ALG Modified CaCO3 as Drug Carriers with the 
Function of Tumor Selective Recognition. J. Mater. Chem. B 2013, 1, 1326-1332. 
11) Guo, Y.; Zhang, J.; Jiang, L.; Shi, X.; Yang, L.; Fang, Q.; Fang, H.; Wang, K.; 
Jiang, K. Facile One-Pot Preparation of Calcite Mesoporous Carrier for Sustained and 
Targeted Drug Release for Cancer Cells. Chem. Commun. 2012, 48, 10636-10638. 
12) Ukrainczyk, M.; Gredicak, M.; Jeric ́, I.; Kralj, D. Interactions of Salicylic Acid 
Derivatives with Calcite Crystals. J. Colloid Interf. Sci. 2012, 365, 296-307. 
13) Peng, H.; Li, K.; Wang, T.; Wang, J.; Wang, J.; Zhu, R.; Sun, D.; Wang, S. 
Preparation of Hierarchical Mesoporous CaCO3 by a Facile Binary Solvent Approach 
as Anticancer Drug Carrier for Etoposide. Nanoscale Res. Lett. 2013, 8, 321. 
14) Wei, W.; Ma, G.; Hu, G.; Yu, D.; Mcleish, T.; Su, Z.; Shen, Z. Preparation of 
Hierarchical Hollow CaCO3 Particles and the Application as Anticancer Drug Carrier. 
J. Am. Chem. Soc. 2008, 130, 15808-15810. 
	   19	  
15) Parakhonskiy, B. V.; Haase, A.; Antolini, R. Sub-Micrometer Vaterite Containers: 
Synthesis, Substance Loading, and Release. Angew. Chem. Int. Ed. 2012, 51, 1195-
1197. 
16) Zhao, D.; Liu, C.; Zhuo, R.; Cheng, S. Alginate/CaCO3 Hybrid Nanoparticles for 
Efficient Codelivery of Antitumor Gene and Drug. Mol. Pharm. 2012, 9, 2887-2893. 
17) Calvaresi, M.; Falini, G.; Bonacchi, S.; Genovese, D.; Fermani, S.; Montalti, M.; 
Prodi, L.; Zerbetto, F. Fullerenol Entrapment in Calcite Microspheres. Chem. Comm. 
2011, 47, 10662-10664. 
18) Hernández-Hernández, A.; Rodríguez-Navarro, A. B.; Gómez-Morales, J.; 
Jiménez-Lopez, C.;  Nys, Y.; García-Ruiz, J. M. Influence of Model Globular 
Proteins with Different Isoelectric Points on the Precipitation of Calcium Carbonate.  
Cryst. Growth Des. 2008, 8, 1495-1502. 
19) Addadi, L.; Raz, S.; Weiner S. Taking Advantage of Disorder: Amorphous 
Calcium Carbonate and its Roles in Biomineralization. Adv. Mater. 2003, 15, 959-
970. 
20) Lowenstam, H.A.; Weiner, S. On biomineralization. Oxford, UK: Oxford 
University Press; 1989. 
21) Mann, S. Biomineralization: Principles and Concepts in Bioinorganic Materials 
Chemistry. New York: Oxford University Press; 2001. 
22) Nudelman, F.; Sommerdijk, N. A. J. M. Biomineralization as an Inspiration for 
Materials Chemistry. Angew. Chem. Int. Ed. 2012, 51, 6582-6596. 
23) Sapsford, K. E.; Russ Algar, W.; Berti, L.; Boeneman Gemmill, K.; Casey, B. J.; 
Oh, E.; Stewart, M. H.; Medintz, I. L. Functionalizing Nanoparticles with Biological 
Molecules: Developing Chemistries that Facilitate Nanotechnology. Chem. Rev. 2013, 
113, 1904–2074. 
	   20	  
24) Schmidt, I.; Lee, K.; Zolotoyabko, E.; Werner, P.; Soup Shim, T.; Oh, Y.-K.; 
Fratzl, P.; Wagermaier, W. Nanocrystalline Calcitic Lens Arrays Fabricated by Self-
Assembly Followed by Amorphous-to-Crystalline Phase Transformation. ACS Nano, 
2014, 8, 9233–9238. 
25) Volodkin , D. V.; Larionova, N. I.; Sukhorukov, G. B. Protein Encapsulation via 
Porous CaCO3 Microparticles Templating. Biomacromolecules, 2004, 5, 1962–1972. 
26) Biradar, S.; Ravichandran, P.; Gopikrishnan, R.; Goornavar, V.; Hall, J. C.; 
Ramesh, V.; Baluchamy, S.; Jeffers, R. B.; Ramesh, G. T. Calcium Carbonate 
Nanoparticles: Synthesis, Characterization and Biocompatibility. J. Nanosci. 
Nanotechnol. 2011, 11, 6868-6674. 
27) Cölfen, H.; Antonietti, M. Crystal Design of Calcium Carbonate Microparticles 
Using Double-Hydrophilic Block Copolymers. Langmuir, 1998, 14, 582–589. 
28) Ogino, T.; Suzuki, T.; Sawada, K. The Formation and Transformation Mechanism 
of Calcium Carbonate in Water. Geochim. Cosmochim. Acta 1987, 51, 2757–2767. 
29) Tannock, I. F.; Rotin, D. Acid pH in Tumors and Its Potential for Therapeutic 
Exploitation. Cancer Res. 1989, 49, 4373-4384. 
30) Pu, H.; Chiang, W.; Maiti, B.; Liao, Z.; Ho, Y.; Shim, M. S.; Chuang, E.; Xia, Y.; 
Sung, H. Nanoparticles with Dual Responses to Oxidative Stress and Reduced pH for 
Drug Release and Anti-inflammatory Applications.  ACS Nano, 2014, 8, 1213–1221 
31)	  Tacar, O.; Sriamornsak, P.; Dass, C. R. Doxorubicin: an Update on Anticancer 
Molecular Action, Toxicity and Novel Drug Delivery Systems. J. Pharm. Pharmacol. 
2013, 65, 157-170.  
32)	  Amelinckx, S. A Dislocation Mechanism for the Growth of Hopper Crystal Faces 
and the Growth of Salol Crystals from Solution and from the Melt. Philos. Mag. 
1953, 44, 337–339. 
	   21	  
 33) Langer, J. S. Instabilities and Pattern Formation in Crystal Growth. Rev. Mod. 
Phys. 1980, 52, 1–28. 
34)  Pokroy, B.; Quintana, J. P.; Caspi, E. N.; Berner, A.; Zolotoyabko, E. 
Anisotropic Lattice Distortions in Biogenic Aragonite. Nature Mater. 2004, 3, 900-
902. 
35) Pokroy, B.; Fitch, A. N.; Marin, F.; Kapon, M.; Adir, N.; Zolotoyabko, E. 
Anisotropic Lattice Distortions in Biogenic Calcite Induced by Intra-Crystalline 
Organic Molecules. J. Struct. Biol. 2006, 155, 96-103. 
36) Pokroy, B.; Fitch, A. N.; Lee, P. L.; Quintana, J. P.; Caspi, E. N.; Zolotoyabko, E. 
Anisotropic Lattice Distortions in the Mollusk-Made Aragonite: A Widespread 
Phenomenon. J. Struct. Biol. 2006, 153, 145-150. 
37) Weber, E.; Bloch, L.; Guth, C.; Fitch, A. N.; Weiss, I. M.; Pokroy, B. 
Incorporation of a Recombinant Biomineralization Fusion Protein into the Crystalline 
Lattice of Calcite. Chem. Mat. 2014, 26, 4925–4932 
38) Pokroy, B.; Fitch, A. N.; Zolotoyabko, E. The Microstructure of Biogenic Calcite: 
A view by High-Resolution Synchrotron Powder Diffraction. Adv. Mater. 2006, 18, 
2363-2368. 
39) Pokroy, B.; Fitch, A. N.; Zolotoyabko, E. Structure of Biogenic Aragonite 
(CaCO3). Cryst. Growth Des. 2007, 7, 1580-1583. 
40) Borukhin, S.; Bloch, L.; Radlauer, T.; Hill, A. H.; Fitch, A. N.; Pokroy, B. 
Screening the Incorporation of Amino Acids into an Inorganic Crystalline Host: the 
Case of Calcite. Adv. Funct. Mater. 2012, 22, 4216-4224. 
41) Brif, A.; Ankonina, G.; Drathen, C.; Pokroy, B. Bio-Inspired Band Gap 
Engineering of Zinc Oxide by Intracrystalline Incorporation of Amino Acids. Adv. 
Mater. 2014, 26, 477-481. 
	   22	  
42) Brif, A.; Bloch, L.; Pokroy, B. Bio-inspired Engineering of a Zinc Oxide/Amino 
Acid Composite: Synchrotron Microstructure Study. CrystEngComm 2014, 16, 3268-
3273. 
43) Larson, A. C.; Von Dreele, R. B. General Structure Analysis System (GSAS). Los 
Alamos National Laboratory Report LAUR 86-748 2000. 
44) Toby, B. H. EXPGUI, a Graphical User Interface for GSAS. J. Appl. Crystallogr. 
2001, 34, 210-213. 
45) Williams, T.; Kelley, C., Gnuplot 4.7: An interactive Plotting Program,  
http://gnuplot.info. 
46) REF STEFANIA 
47) REF STEFANIA 
 
Corresponding	  Author *	  BP:	  bpokroy@tx.technion.ac.il;	  SR:	  stefania.rapino3@unibo.it;	  	  GF:	  giuseppe.falini@unibo.it;	  MC:	  matteo.calvaresi3@unibo.it	  
Author	  Contributions	  The	  manuscript	  was	  written	  through	  contributions	  of	  all	  authors.	   
 
Graphical Table of Contents  
 
 
	   23	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
